ADVA launches auto-tunable transceiver to help operators easily scale access networks to 25G
15.9.2022 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its AccessWave25™, empowering network operators to easily migrate their 10Gbit/s access infrastructure to 25Gbit/s connectivity without a significant increase in footprint or major changes to the existing optical layer. The pluggable device answers the urgent need for higher bandwidth services in mobile X-Haul, cable access and wholesale networks. Operators can now slot the AccessWave25™ into any standard-based SFP28 port for an instant capacity upgrade without replacing existing demarcation or aggregation devices. Using patent-pending distance optimization technology, the device also extends 25Gbit/s DWDM reach to 40km, and its G.metro auto-tuning technology reduces provisioning efforts and simplifies operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005787/en/
ADVA’s AccessWave25™ offers an easy route to 25G DWDM connectivity in access networks without any major upgrades. (Photo: Business Wire)
“Our AccessWave25™ is the key to unlocking more bandwidth at the edge. Now network operators have an easy, low-cost way to address soaring bandwidth consumption that doesn’t require extra real estate or cause major disruption to services. And as well as boosting capacity, the AccessWave25™ offers a substantial increase in reach. While today’s solutions can’t go beyond 15km, our new pluggable device uses PAM4 modulation and direct-detection technology to support data transport up to 40km,” said Christoph Glingener, CEO of ADVA. “Simple to deploy and ideally suited for outdoor use, our AccessWave25™ device will be the foundation for the next generation of optical access networks.”
ADVA’s AccessWave25™ plug enables the seamless upgrade of fiber-based access networks. Host-agnostic and with a standardized SFP28 form factor, it empowers operators to instantly connect switches, routers and many other devices to DWDM open line systems. With full C-band tunable interfaces and G.metro self-tuning capabilities, the device reduces set-up time, minimizes human error and delivers operational cost savings. Network operators can also use the G.metro communication channel to remotely monitor the status and health of plugs for easy troubleshooting of any issues. Using less than 3 watts and with an I-temp hardened design, the AccessWave25™ is perfect for deployment in a wide range of outdoor settings.
“The latest addition to our pluggable technology portfolio answers the most urgent needs of our customers in a wide range of industries. From the core to the metro to access networks, our product range offers a plug for almost every situation,” commented Saeid Aramideh, VP of business development at Optical Engines, ADVA. “OurAccessWave25™ is a vital addition to our AccessWave™ family of pluggable devices and features our latest G.metro technology. Either with a third-party OLS or with our turnkey FSP 3000 solution for passive optical access networks, our pluggable technology provides the tools for tackling relentless growth in data consumption as well as the ever-changing demands of optical access networks.”
Further details on the ADVA AccessWave25™ are available in these slides: https://adva.li/accesswave25-slides.
A supporting product video is also available here: https://youtu.be/bcV06nMJ3_c.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005787/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom